Perspective Therapeutics (CATX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CATX Perspective Therapeutics

Watchlist

3.4700
+0.4700+15.67%

Close Nov 22 16:00 ET

3.5100
+0.0400+1.15%

Post 20:02 ET

234.53MMarket Cap-2328P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Perspective Therapeutics Price Target Cut to $16.00/Share From $22.00 by Oppenheimer
Dow JonesNov 22 09:32 ET · Ratings
Perspective Therapeutics Is Maintained at Outperform by Oppenheimer
Dow JonesNov 22 09:32 ET · Ratings
Perspective Therapeutics Analyst Ratings
BenzingaNov 22 09:20 ET · Ratings
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $16
Moomoo NewsNov 22 08:31 ET · Ratings
Truist Financial Releases a Buy Rating on Perspective Therapeutics (CATX)
TipRanksNov 22 07:15 ET · Ratings
Perspective Therapeutics Selloff a Buying Opportunity, Says JonesResearch
TipRanksNov 22 06:00 ET

Comments

Jaguar8

14 hours ago

Easy 16% 😉

$Perspective Therapeutics (CATX.US)$

Johnny Mnemonic

17 hours ago

I don't trust nobody
I don't even trust my mind
losing everybody
they can never take my grind

Jaguar8

Yesterday 13:09

On watchlist. Reason: Presentation today. Possible PR tomorrow

$Perspective Therapeutics (CATX.US)$

Stock_Drift

Nov 15 16:17

After Hours Ticks. 5:16pm 11/15🦌

$Scorpius Holdings (SCPX.US)$ $Perspective Therapeutics (CATX.US)$ $Turbo Energy (TURB.US)$ $Adverum Biotechnologies (ADVM.US)$ $NFT Ltd (MI.US)$ $Xylo Technologies (XYLO.US)$ $Lipocine (LPCN.US)$ $Massimo (MAMO.US)$ $China Jo-Jo Drugstores (CJJD.US)$ $Edesa Biotech (EDSA.US)$ $Atara Biotherapeutics (ATRA.US)$ $Eterna Therapeutics (ERNA.US)$ $DDC Enterprise (DDC.US)$
📊⚡️📊

Trytosaveabit

Nov 15 15:13

Watching! Note the dates!

$Perspective Therapeutics (CATX.US)$ Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium t...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

CATX Perspective Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target